Biosimilar allergy drug trial halted after just one volunteer
NCT ID NCT04361812
First seen Nov 21, 2025 · Last updated May 20, 2026 · Updated 23 times
Summary
This study aimed to see if a new drug called HS632 works the same in the body as the approved allergy drug Xolair (omalizumab). It was planned for healthy male volunteers, but only one person joined before the study was stopped. The main goal was to compare how the body processes each drug and check for safety issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SIMILARITY OF PHARMACOKINETICS AND SAFETY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Peng
Shanghai, Shanghai Municipality, 200040, China
Conditions
Explore the condition pages connected to this study.